Semaglutide maka ụdị ọrịa shuga 2
Nkọwa ngwaahịa
| Aha | Semaglutide |
| Nọmba CAS | 910463-68-2 |
| Usoro ihe omimi | C187H291N45O59 |
| Ibu arọ molekụla | 4113.57754 |
| Nọmba EINECS | 203-405-2 |
Ụdị okwu
Sermaglutide; Semaglutide fandachem; Semaglutide adịghị ọcha; Sermaglutide USP/EP; semaglutide; Sermaglutide CAS 910463 68 2; Ozempic,
Nkọwa
Semaglutide bụ ọgbọ ọhụrụ nke GLP-1 (glucagon-dị ka peptide-1) analogs, yana semaglutide bụ ụdị usoro onunu ogwu na-eme ogologo oge nke emepụtara dabere na ntọala nke liraglutide, nke nwere mmetụta dị mma na ọgwụgwọ ụdị ọrịa shuga 2. Novo Nordisk emechaala 6 Phase IIIa ọmụmụ nke semaglutide injection, ma nyefee akwụkwọ ndebanye aha ọgwụ ọhụrụ maka ọgwụ mgbochi semaglutide kwa izu na US Food and Drug Administration (FDA) na December 5, 2016. A na-edozikwa ngwa ikike ahịa ahịa (MAA) na Ụlọ Ọrụ Ọgwụ na Europe (EMA).
E jiri ya tụnyere liraglutide, semaglutide nwere ogologo aliphatic agbụ na ụba hydrophobicity, mana semaglutide na-eji obere yinye PEG gbanwee, na hydrophilicity ya na-abawanye nke ukwuu. Mgbe mgbanwe PEG gasịrị, ọ bụghị naanị na ọ ga-ejikọta ya na albumin, na-ekpuchi ebe enzymatic hydrolysis nke DPP-4, ma na-ebelata excretion renal, gbasaa ọkara ndụ ndụ, ma nweta mmetụta nke mgbasa ozi ogologo oge.
Ngwa
Semaglutide bụ ụdị usoro onunu ogwu na-eme ogologo oge nke emepụtara dabere na ntọala ntọala nke liraglutide, nke dị irè karị n'ịgwọ ụdị ọrịa shuga 2.
Bioactivity
Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC0113-0217) bụ glucagon dị ka peptide 1 (GLP-1) na-eme ogologo oge, onye agonist nke GLP-1receptor, nwere ụdị 2 Therapeutic irè nke ọrịa shuga mellitus (T2DM).
Ogo Sistemu
N'ozuzu, usoro mma na mmesi obi ike dị na-ekpuchi ọkwa niile nke mmepụta nke ngwaahịa emechara. A na-arụ ọrụ nrụpụta na njikwa zuru oke nke kwekọrọ na usoro/ nkọwapụta akwadoro. Usoro njikwa mgbanwe na njikwa ngbanwe dị, na nyocha na nyocha mmetụta dị mkpa dị mkpa. A na-eme usoro kwesịrị ekwesị iji hụ na ngwaahịa dị mma tupu ahapụ ya n'ahịa.
